Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandra Leary

Showing results (161-170 of 217) with videos related to

Pageof 22
Sort By:
The Lancet. Oncology|June 18, 2021
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 studyEric Pujade-Lauraine, Keiichi Fujiwara, Jonathan A Ledermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2020
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA TrialBenoit You, Patrick Robelin, Michel Tod, et al.
Gynecologic Oncology|October 23, 2022
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinomaDavid M O'Malley, Amit M Oza, Domenica Lorusso, et al.
British Journal of Cancer|January 23, 2023
Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistryLisa Vermij, Jan J Jobsen, Alicia León-Castillo, et al.
Journal for Immunotherapy of Cancer|June 24, 2021
Metabolic features of cancer cells impact immunosurveillanceAdrien Joseph, Pan Juncheng, Michele Mondini, et al.
Gynecologic Oncology|June 4, 2023
Corrigendum to "A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer"Félix Blanc-Durand, Elisa Yaniz-Galende, Alba Llop-Guevara, et al.
Gynecologic Oncology|March 3, 2023
A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancerFélix Blanc-Durand, Elisa Yaniz-Galende, Alba Llop-Guevara, et al.
Molecular Cancer|August 13, 2024
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker researchAurélie Moniot, Christophe Schneider, Laure Chardin, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 22, 2024
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomesLucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
Gynecologic Oncology|October 4, 2021
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancerElizabeth M Swisher, Rebecca S Kristeleit, Amit M Oza, et al.
Pageof 22

Showing results (161-170 of 217) with videos related to

Sort By:
Pageof 22
The Lancet. Oncology|June 18, 2021
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 studyEric Pujade-Lauraine, Keiichi Fujiwara, Jonathan A Ledermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2020
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA TrialBenoit You, Patrick Robelin, Michel Tod, et al.
Gynecologic Oncology|October 23, 2022
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinomaDavid M O'Malley, Amit M Oza, Domenica Lorusso, et al.
British Journal of Cancer|January 23, 2023
Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistryLisa Vermij, Jan J Jobsen, Alicia León-Castillo, et al.
Journal for Immunotherapy of Cancer|June 24, 2021
Metabolic features of cancer cells impact immunosurveillanceAdrien Joseph, Pan Juncheng, Michele Mondini, et al.
Gynecologic Oncology|June 4, 2023
Corrigendum to "A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer"Félix Blanc-Durand, Elisa Yaniz-Galende, Alba Llop-Guevara, et al.
Gynecologic Oncology|March 3, 2023
A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancerFélix Blanc-Durand, Elisa Yaniz-Galende, Alba Llop-Guevara, et al.
Molecular Cancer|August 13, 2024
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker researchAurélie Moniot, Christophe Schneider, Laure Chardin, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 22, 2024
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomesLucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
Gynecologic Oncology|October 4, 2021
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancerElizabeth M Swisher, Rebecca S Kristeleit, Amit M Oza, et al.
Pageof 22